CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

29/11/2024

1

Speculative Buy

$10.00

56.01%

The Clarity Pharmaceuticals' AGM provided various updates including the start of recruitment for the Co-PSMA trial, notes Bell Potter. Data from previous trials strongly suggested 64Cu SAR-bisPSMA will outperform 68Ga-PSMA11 in the detection of early-stage tumours.

Management also noted the last patient in the Disco trial evaluating the 64Cu SARTATE asset for the imaging of Neuroendocrine tumours has completed his/her final assessment. Next step is release of final results in the 1H of 2025, highlights the broker.

The Speculative Buy rating is maintained with $10 target price.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -18.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -21.60 cents.

06/11/2024

1

Overweight

$8.48

32.29%

Wilsons assigns an Overweight rating to both Telix Pharmaceuticals ((TLX)) and Clarity Pharmaceuticals, with target prices of $25.00 and $8.48, respectively.

On an un-risked basis the analyst has a target price for Telix at $50 and and $21.14 for Clarity, citing promising growth in radiopharmaceutical diagnostics following the Centers for Medicare & Medicaid Services' 2025 final rule on pricing stability.

For Telix, the broker highlights the competitive advantage of Illucix in PSMA PET/CT scanning, with pricing stability set to support its market share until the launch of its next-generation TLX007-CDx in mid-2025.

Clarity is positioned to capture up to 30% of the PSMA PET/CT market with its 64Cu-SAR-bisPSMA tracer, leveraging potential clinical differentiation, including the ability to detect additional lesions.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -13.40 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -17.10 cents.